


Diffuse Large B-cell Lymphoma Communication Roadmap (DLBCL)



Diffuse Large B-cell Lymphoma Communication Roadmap

Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease affecting B-lymphocytes. There are many novel therapies and combination regimens currently being studied in clinical trials for the treatment of both newly diagnosed and relapsed/refractory DLBCL. Recently approved treatments, as well as those on the horizon, provide new hope for patients as therapeutic options become more targeted to and personalized for their disease. With these recent advancements, community cancer programs need to be educated on the role these therapies will play in the community setting and how best to integrate these new treatments into practice.

In response, the Association of Cancer Care Centers (ACCC) has developed a "Communication Roadmap," highlighting effective practices to support patients with DLBCL applied along the care continuum.

THE BASICS

30% of cases of non-Hodgkin lymphomas (NHL) are DLBCL in the United States.¹

30,000 new cases of DLBCL are diagnosed annually in the US.²

REFERENCES

1. The Leukemia & Lymphoma Society. NHL subtypes. 2022. Accessed September 21, 2023. lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes.
2. Padala SA, Kallam A. (2022). Diffuse large B cell lymphoma - statpearls - NCBI bookshelf. [ncbi.nlm.nih.gov/books/NBK557796](https://www.ncbi.nlm.nih.gov/books/NBK557796). Accessed May 4, 2023.
3. Staff H. Most blood cancer mutations due to DNA replication errors. MDedge Hematology and Oncology. March 24, 2017. Accessed August 9, 2023. [mdedge.com/hematology-oncology/article/185807/leukemia-myelodysplasia-transplantation/most-blood-cancer-mutations-due-dna](https://www.mdedge.com/hematology-oncology/article/185807/leukemia-myelodysplasia-transplantation/most-blood-cancer-mutations-due-dna).
4. Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. *Blood* 130, 1800–1808. doi. [org/10.1182/blood-2017-03-769620](https://doi.org/10.1182/blood-2017-03-769620) (2017).

This project is supported by:

abbvie

Genentech
A Member of the Roche Group

Genmab

A publication from the ACCC education program, "Reframing the Conversation: Effective Practices for Diffuse Large B-cell Lymphoma." Learn more at acc-cancer.org/DLBCL.

The **Association of Cancer Care Centers (ACCC)** provides education and advocacy for the cancer care community. For more information, visit acc-cancer.org.

© 2024. Association of Cancer Care Centers.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.